Zevra Therapeutics (ZVRA) EBT (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly EBT came in at $44.8 million in Q1 2026, up 2437.19% YoY from $1.8 million in Q1 2025, and up 253.73% on a QoQ basis from $12.7 million in Q4 2025.
Zevra Therapeutics (ZVRA) EBT (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of EBT data on file, last reported at $44.8 million in Q1 2026.
- Quarterly EBT rose 2437.19% year-over-year to $44.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.4 million (up 277.0% YoY) and the FY2025 annual result came in at $86.7 million, up 196.16% from the prior year.
- EBT improved to $44.8 million in Q1 2026, from $12.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of $76.9 million in Q2 2025 to a low of -$33.2 million in Q3 2024.
- A 5-year average of -$1.5 million and a median of -$5.7 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT tumbled 650.09% — and 2026, when it soared 2437.19%.
- Tracing ZVRA's EBT over 5 years: stood at -$3.0 million in 2022, then plunged by 561.74% to -$19.9 million in 2023, then fell by 2.39% to -$20.4 million in 2024, then soared by 162.19% to $12.7 million in 2025, then soared by 253.73% to $44.8 million in 2026.
- The last three EBT figures came in at $44.8 million (Q1 2026), $12.7 million (Q4 2025), and -$977000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 12.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.79 Mn |
| Mar 31, 2026 | 44.80 Mn |
| Dec 31, 2025 | 12.67 Mn |
| Sep 30, 2025 | -977,000.00 |
| Jun 30, 2025 | 76.91 Mn |
| Mar 31, 2025 | -1.92 Mn |
| Dec 31, 2024 | -20.37 Mn |
| Sep 30, 2024 | -33.23 Mn |
| Jun 30, 2024 | -19.86 Mn |
| Mar 31, 2024 | -16.69 Mn |
| Dec 31, 2023 | -19.89 Mn |
| Sep 30, 2023 | -10.19 Mn |
| Jun 30, 2023 | -2.65 Mn |
| Mar 31, 2023 | -13.32 Mn |
| Dec 31, 2022 | -3.01 Mn |
| Sep 30, 2022 | -5.70 Mn |
| Jun 30, 2022 | -21.93 Mn |
| Mar 31, 2022 | 10.48 Mn |
| Dec 31, 2021 | -2.67 Mn |
| Sep 30, 2021 | -1.76 Mn |